Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zan-81
- Development stage
- Preclinical
- Lead developer
- Corellia AI
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zan-81 is an antibody-drug conjugate (ADC) being developed by Corellia AI for the treatment of HER2-positive relapsed or refractory breast cancer, specifically targeting patients who have progressed after treatment with trastuzumab deruxtecan (Enhertu). The drug utilizes Corellia AI's proprietary Coromip technology to conjugate a HER2-targeting monoclonal antibody with Omipalisib (also known as compound '81'), a potent dual inhibitor of PI3K and mTOR. By delivering the PI3K/mTOR inhibitor directly to HER2-expressing cancer cells, Zan-81 aims to overcome resistance mechanisms associated with the PI3K/AKT/mTOR pathway while minimizing systemic toxicity. It is currently in the discovery and preclinical stages of development.
- Other names
- Zan-81-Corellia AI-HER2-PI3K/mTOR (Omipalisib warhead)-ADC
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Zan-81.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zan-81.